News

GBAICTI and the BAY TRIAL signed a Memorandum of Understanding on July 29, 2025 to strengthen collaboration between Shenzhen and Hong Kong in the field of clinical research at the Clinical Trial Collaboration meeting, continuing to promote cross-border medical collaboration between the two places.
 
During the meeting, representatives from both Hong Kong and Shenzhen had in-depth exchanges and discussions on the Implementation Plan for Collaborative Advancement of International Clinical Trials in the GBA. This included the latest developments and proposed services of the GBA Clinical Trial Collaboration Platform, which will be jointly established by the end of this year. The key areas include project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; introduction of artificial intelligence technologies to assist with matching of clinical trial institutions and researchers, as well as offering consultation services; establishment of a co-ordinated ethics review mechanism between the two places to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; building of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on diseases in which Shenzhen and Hong Kong have advantages. In addition, the Shenzhen and Hong Kong sides also discussed further integrating the measure of using Hong Kong-registered drugs and medical devices used in Hong Kong public hospitals in the GBA with real-world studies in an effective manner, exploring the use of real-world data to support drug registration and approval in the Mainland at the meeting.